"Australia Pharmaceuticals & Healthcare Report Q3 2016" Published

Drugmakers operating in Australia will face an increasingly challenging business environment as the Sixth Pharmacy Community Agreement's measures come into effect. This includes a 5% price cut to medicines listed on the F1 formulary for more than five years, as well as changes to the calculation used in the price disclosure cycle. Critically, we highlight that biosimilar substitutability and naming will be a growing area of contention between originator firms and authorities who seek to curtail spending due to the exponential increase in biologics expenditure over the past few years.Headline Expenditure ProjectionsPharmaceuticals : AUD14.0bn (USD10.5bn) in 2015 to AUD14.5bn (USD9.6bn) in 2016; +3.4% in local currency terms and -8.6% in US dollar terms, due to significant exchange rate fluctuations.

Full Report Details at
- http://www.fastmr.com/prod/1172822_australia_pharmaceuticals.aspx?afid=301

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- Brazil Pharmaceuticals & Healthcare Report Q3 2016
- Czech Republic Pharmaceuticals & Healthcare Report Q3 2016
- Bahrain Pharmaceuticals & Healthcare Report Q3 2016
- China Pharmaceuticals & Healthcare Report Q3 2016
- Egypt Pharmaceuticals & Healthcare Report Q3 2016